News As COVID vaccine and Paxlovid sales decline, analysts want to know what’s next for Pfizer Jan 6, 2023 admin [ad_1] Pfizer PFE, +0.28% is the latest pandemic stock to face questions about its long-term strategy as revenue from its COVID-19 vaccine and antiviral business starts to dry up. Bank…
As COVID vaccine and Paxlovid sales decline, analysts want to know what’s next for Pfizer
[ad_1] Pfizer PFE, +0.28% is the latest pandemic stock to face questions about its long-term strategy as revenue from its COVID-19 vaccine and antiviral business starts to dry up. Bank…